Caren van Roekel

90 Chapter 3 TABLE 1. Overview of literature First author, year Treatment arm Control arm n (Y-RE/ other) Primary tumor(s) RE approach Questionnaires Scale range Timing Outcome Solely Y-RE Cosimelli, 2010 (15) Y-RE - 14 a Colorectal Whole liver, re-RE in 3 patients QLQ-C30, QLQ-LMC21, QLQ-CR38 0-100 Baseline, 6 weeks QoL was not adversely affected Kalinowski, 2009 (16) Y-RE - 9 Neuroendocrine tumour 7 patients whole liver, 2 patients bilobar with re-RE QLQ-C30, QLQ- LMC21 0-100 Baseline, 3-monthly (up to 44 months) After 6 months, QoL significantly improved Salem, 2013 (17) Y-RE TACE b 29/27 HCC c 20 patients lobar, 9 patients segmental Fact-Hep 0-180 Baseline, 2 weeks, 4 weeks No significant difference between arms Steel, 2004 (18) Y-RE TACE 14/14 HCC Whole liver Fact-Hep 0-180 Baseline, 3 months, 6 months, 1 year At 3 months, significantly higher QoL scores for Y-RE group than control group. No significant difference at 6 months Kolligs, 2015 (19) Y-RE TACE 8/10 d HCC 5 patients lobar, 1 patient segmental, 7 patients whole liver Fact-Hep 0-180 Baseline, 6 weeks, 12 weeks No significant difference between groups